NCT00114049已完成3 期
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- Difference between treatments over time based on pain intensity and pain relief scores.
研究概览
简要总结
The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
详细描述
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg, and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Difference between treatments over time based on pain intensity and pain relief scores.
次要结局
- Difference between treatments based on changes in onset, duration of activity, overall effectiveness, and patient based assessments.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The KneeOsteoarthritis, KneeNCT00120900GlaxoSmithKline1,340
已完成
3 期
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumMuscle WastingNon-Small Cell Lung CancerNCT01355497GTx330
已完成
3 期
COX-2 Inhibitor Study In Patients With Rheumatoid ArthritisArthritis, RheumatoidNCT00113308GlaxoSmithKline2,208
已完成
3 期
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)Muscle WastingNon Small Cell Lung CancerNCT01355484GTx321
终止
2 期
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)Triple Negative Breast CancerNCT02368691GTx32